Legal & General Group’s MaxCyte MXCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-8,963
Closed -$6.3K 3489
2026
Q1
$6.3K Hold
8,963
﹤0.01% 3258
2025
Q4
$13.9K Hold
8,963
﹤0.01% 3160
2025
Q3
$14.2K Hold
8,963
﹤0.01% 3182
2025
Q2
$19.5K Sell
8,963
-16,207
-64% -$39.2K ﹤0.01% 3010
2025
Q1
$68.2K Sell
25,170
-956
-4% -$3.77K ﹤0.01% 2696
2024
Q4
$107K Sell
26,126
-74,444
-74% -$281K ﹤0.01% 2719
2024
Q3
$392K Buy
100,570
+3,877
+4% +$16.3K ﹤0.01% 2541
2024
Q2
$380K Buy
96,693
+12,061
+14% +$51.9K ﹤0.01% 2511
2024
Q1
$355K Buy
84,632
+3,810
+5% +$17.9K ﹤0.01% 2559
2023
Q4
$380K Buy
80,822
+6,718
+9% +$26.2K ﹤0.01% 2557
2023
Q3
$231K Buy
74,104
+14,288
+24% +$57.4K ﹤0.01% 2692
2023
Q2
$275K Buy
59,816
+31,308
+110% +$144K ﹤0.01% 2664
2023
Q1
$141K Buy
28,508
+1,785
+7% +$8.79K ﹤0.01% 2702
2022
Q4
$146K Buy
26,723
+1,149
+4% +$7.05K ﹤0.01% 2713
2022
Q3
$166K Sell
25,574
-174,274
-87% -$972K ﹤0.01% 2685
2022
Q2
$942K Sell
199,848
-2,062
-1% -$10.2K ﹤0.01% 2185
2022
Q1
$1.43M Sell
201,910
-205,552
-50% -$1.4M ﹤0.01% 2111
2021
Q4
$4.16M Sell
407,462
-443,174
-52% -$4.76M ﹤0.01% 1673
2021
Q3
$10.4M Buy
+850,636
New +$12.8M ﹤0.01% 1159

Other funds holding MXCT

Legal & General Group's MXCT Position: Q2 2026 in Review

Legal & General Group sold out of MaxCyte (MXCT) in Q2 2026, closing a stake of 8,963 shares — an estimated $6.3K sold.

Legal & General Group first reported a position in MXCT in Q3 2021 and held it in 19 quarters. The position peaked at $10.4M in Q3 2021. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

  • Legal & General Group reported no remaining MaxCyte position as of Q2 2026 after selling out during the quarter.
  • Legal & General Group sold 8,963 MaxCyte shares in Q2 2026, an estimated $6.3K.
  • Legal & General Group first reported a position in MaxCyte in Q3 2021 and held it in 19 quarters.
  • Legal & General Group's MaxCyte position peaked at $10.4M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.